The current generation of GLP-1 receptor agonists includes: Semaglutide (weekly subcutaneous injection or oral formulation) Liraglutide (daily subcutaneous injection) Tirzepatide (dual GLP-1/GIP receptor agonist, weekly subcutaneous injection) Each of these GLP-1 agents carries a distinct pharmacological profile, and the optimal choice depends on a patients clinical history, metabolic risk factors, and therapeutic goals a determination best made in consultation with a physician experienced in metabolic and longevity medicine
(A head-to-head trial of the two medications, funded by Eli Lilly, found that patients on Zepbound lost an average of 20 percent of their weight, versus about 14 percent for those on Wegovy.) Nevertheless, its much harder to get Zepbound than Wegovy
Research consistently shows that resistance exercise is the single most effective intervention for preserving lean mass during caloric restriction
[PMID: 4307206] PubMed record related to this compound for laboratory literature review
Gastrointestinal symptoms such as nausea, regurgitation, and diarrhea are among the most frequently reported
These findings highlight the enhanced benefits of combining medication with lifestyle adjustments
